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ABSTRACT
Purpose. The purpose of the NBRST study is to compare
a multigene classifier to conventional immunohistochem-
istry (IHC)/fluorescence in situ hybridization (FISH)
subtyping to predict chemosensitivity as defined by path-
ological complete response (pCR) or endocrine sensitivity
as defined by partial response.
Methods. The study includes women with histologically
proven breast cancer, who will receive neoadjuvant che-
motherapy (NCT) or neoadjuvant endocrine therapy.
BluePrint in combination with MammaPrint classifies
patients into four molecular subgroups: Luminal A,
Luminal B, HER2, and Basal.
Results. A total of 426 patients had definitive surgery.
Thirty-seven of 211 (18 %) IHC/FISH hormone receptor
(HR)?/HER2- patients were reclassified by Blueprint as
Basal (n = 35) or HER2 (n = 2). Fifty-three of 123 (43 %)
IHC/FISH HER2? patients were reclassified as Luminal
(n = 36) or Basal (n = 17). Four of 92 (4 %) IHC/FISH
triple-negative (TN) patients were reclassified as Luminal
(n = 2) or HER2 (n = 2). NCT pCR rates were 2 % in
Luminal A and 7 % Luminal B patients versus 10 % pCR
in IHC/FISH HR?/HER2- patients. The NCT pCR rate
was 53 % in BluePrint HER2 patients. This is significantly
superior (p = 0.047) to the pCR rate in IHC/FISH HER2?
patients (38 %). The pCR rate of 36 of 75 IHC/FISH
HER2?/HR? patients reclassified as BPLuminal is 3 %.
NCT pCR for BluePrint Basal patients was 49 of 140
(35 %), comparable to the 34 of 92 pCR rate (37 %) in
IHC/FISH TN patients.
Conclusions. BluePrint molecular subtyping reclassifies
22 % (94/426) of tumors, reassigning more responsive
patients to the HER2 and Basal categories while reas-
signing less responsive patients to the Luminal category.
These findings suggest that compared with IHC/FISH,
BluePrint more accurately identifies patients likely to
respond (or not respond) to NCT.
Classification by molecular subtype has been recom-
mended as a guide for the selection of therapy for patients
with breast cancer. However, at present, the methodology
for molecular subtyping is not standardized and the meth-
odology and interpretation of results vary between different
laboratories. Subtype is being assigned using conventional
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immunohistochemistry (IHC) and fluorescence in situ
hybridization (FISH) (‘‘conventional subtype’’) or molec-
ularly using gene expression profiling.
Neoadjuvant trials allow for rapid assessment of treat-
ment sensitivity, and pathological complete response
(pCR) has been proposed as a surrogate endpoint for
longer-term outcome. One recently available molecular
profile is BluePrint. The profile determines the mRNA
levels of 80 genes that discriminate between three breast
cancer subtypes based on functional molecular pathways:
Luminal, HER2, and Basal.1 A further stratification of the
Luminal group into types A and B is important to identify
the risk of metastasis and has been related to tumor grade
and/or proliferation (Ki-67 fraction or mitosis).2 However,
risk stratification by multigene assays, such as Mamma-
Print, is superior for making this distinction, whereby the
MammaPrint low-risk patients are identified as Luminal A
and MammaPrint high risk corresponds to Luminal B.
In a retrospective analysis, the molecular stratification of
patients with BluePrint and MammaPrint was used to corre-
late the response to neoadjuvant chemotherapy and long-term
outcomes in patients with early-stage or locally advanced
breast cancer. Patients (n = 435) had been enrolled in four,
independent, neoadjuvant chemotherapy clinical trials (I-
SPY 1 trial, two trials at the University of Texas M.D.
Anderson Cancer Center, and a trial from the City of Hope
National Medical Center). The pCR rate differed substantially
in the different molecular subgroups: 6 % in the Luminal A;
11 % in Luminal B; 48 % in the HER2; and 37 % in the Basal
groups. Luminal A (MammaPrint Low Risk) patients had a
good prognosis with excellent survival and seemed not to
benefit from chemotherapy. A marked benefit in response and
DMFS to neoadjuvant treatment in patients subtyped as
HER2 and Basal was observed.3
The objective of the current prospective NBRST study is
to compare chemosensitivity as defined by pCR or endo-
crine sensitivity as defined by partial response (PR) for
patients classified with the 80-gene BluePrint functional
subtype profile to conventional IHC/FISH subtyping.
PATIENTS AND METHODS
Patients
Patients with histologically proven breast cancer, who
had started or were scheduled to start neoadjuvant che-
motherapy therapy or neoadjuvant hormone therapy after
successful MammaPrint/BluePrint assay, were enrolled in
the prospective NBRST registry trial between June 2011
and October 2013 from 40 institutes in the United States.
The protocol was approved by institutional review boards
at all participating institutions. All patients provided writ-
ten, informed consent for participation in the study.
Excluded from the study were patients who had an exci-
sional biopsy or axillary dissection, confirmed distant
metastatic disease, any prior chemotherapy, radiotherapy,
or endocrine therapy for the treatment of breast cancer and
any serious uncontrolled, intercurrent infections, or other
serious uncontrolled concomitant disease. Treatment was at
the discretion of the physician adhering to NCCN approved
or other peer-reviewed, established regimens.
Molecular and Clinical Subtyping
Fresh (n = 120) or formalin fixed paraffin embedded
tumor samples (n = 306) were obtained from core needle
biopsies. Microarray analysis (RNA labelling, microarray
hybridization, and scanning) for obtaining the 80-gene
BluePrint subtype and 70-gene MammaPrint profiles was
performed at the centralized Agendia Laboratory blinded
for clinical and pathological data. RNA was cohybridized
with a standard reference to the custom-designed diag-
nostic chip, each containing oligonucleotide probes for the
profiles in triplicate or more.
BluePrint stratifies into three distinct molecular sub-
groups: Luminal (BPLuminal), HER2 (BPHER2), and
Basal (BPBasal). MammaPrint substratifies BPLuminal
into Luminal A (BPLuminalA for MammaPrint Low Risk)
and Luminal B (BPLuminalB for MammaPrint High Risk).
Hormone receptor (HR) status (ER and PR) and HER2
status were determined locally on pretreatment core biop-
sies. Both ER and PR status were determined by IHC and
were considered positive if there was C1 % positive
staining. HER2 status was determined by IHC and/or FISH
assays locally. HER2 status was regarded as positive if
there was 3? staining and/or FISH positivity.
Statistical Analysis
In the ongoing NBRST registry, for neoadjuvant che-
motherapy patients the primary endpoint is pCR, which is
defined as the absence of invasive carcinoma in both the
breast and axilla at microscopic examination of the resec-
tion specimen, regardless of the presence of carcinoma
in situ. PR is defined as C30 % reduction in the tumor area.
PR is a secondary endpoint for neoadjuvant chemotherapy
patients and the primary endpoint for neoadjuvant endo-
crine therapy patients. Rates of pCR were calculated for
each BluePrint/MammaPrint molecular subtype and com-
pared with pCR rates for subgroups classified by IHC/
FISH. The response rates are presented as a proportion of
all patients treated with NCT. Comparison of response
rates is conducted using a two-tailed z-test for two popu-
lation proportions. The null hypothesis is that there is no
difference between these two population proportions.
Hence, a p value less than the significance level of 0.05
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means that the null hypothesis cannot be accepted; pro-
portions are different. All calculations were performed with
SPSS statistical package version 16.0 (SPSS, Chicago, IL).
RESULTS
A total of 426 patients (age range 22–82), T1-4 N0-3,
underwent surgical resection and had pCR information
available. Clinical characteristics are shown in Table 1. Of
the 426 patients, 59 (14 %) were classified as BPLumin-
alA, 153 (36 %) patients were classified as BPLuminalB,
74 patients (17 %) were classified as BPHER2, and 140
patients (33 %) were classified as BPBasal. According to
pathological assessment, 211 patients (50 %) were IHC/
FISH HR?/HER2-, 123 (29 %) were IHC/FISH HER2?
(of whom 75 were HR? and 48 were HR-), and 92 (22 %)
patients were IHC/FISH triple-negative (TN). Most
patients had T2 or T3 tumors (85 %) and clinically or
pathologically confirmed axillary lymph node involvement
(56 %) at time of diagnosis; 93 % had tumors of inter-
mediate or high histologic grade; 86 % of patients were
classified as high risk by MammaPrint.
IHC Versus BluePrint/MammaPrint-Based
Classification
We evaluated the distribution of patients within the
conventional IHC/FISH subclassification and as reclassi-
fied by BluePrint molecular subtype as illustrated in
Table 2. In total, 22 % (94/426) of patients were reclassi-
fied into a different BluePrint/MammaPrint molecular
subgroup compared with conventional (IHC/FISH) sub-
typing; 37 of 211 (18 %) IHC/FISH luminal (HR?/
HER2-) patients were not BPLuminal (35 BPBasal and 2
BPHER2). Fifty-three of 123 (43 %) IHC/FISH HER2?
patients were not BPHER2 (36 BPLuminal and 17 BPBa-
sal). Four of 92 (4 %) IHC/FISH TN patients were not
BPBasal (2 BPLuminal and 2 BPHER2). The BPLuminal
patients were further stratified with MammaPrint into
BPLuminalA (n = 59) and BPLuminalB (n = 153).
TABLE 1 Clinical characteristics for patients as classified according to BluePrint and MammaPrint
Characteristic Luminal A Luminal B HER2 Basal Total
(n = 59) (n = 153) (n = 74) (n = 140) (N = 426)
Median age (range), years 57 (33–78) 54 (22–80) 52 (23–73) 51 (28–79) 52 (22-80)
T stage
1 3 13 5 17 38
2 33 92 38 88 251
3 20 38 24 31 113
4 3 10 6 4 23
Missing 0 0 1 0 1
N stage
0 30 48 22 65 165
1–3 24 95 48 70 237
Missing 5 10 4 5 24
Grade
1 10 7 2 1 20
2 43 73 29 20 165
3 5 66 43 119 233
Missing 1 7 0 0 8
MammaPrint
Low risk 59 0 2 0 61
High risk 0 153 72 140 365
TABLE 2 Conventional (IHC/FISH) subtype versus BluePrint/
MammaPrint molecular subtype
IHC/FISH BluePrint/MammaPrint Total
Luminal A Luminal B HER2 Basal
HR?/HER2- 51 123a 2 35b 211
HER2? (HR?) 8 28 33 6 75
HER2? (HR-) 0 0 37 11 48
Triple negative 0 2 2 88c 92
Total 59 153 74 140 426
a 5 HER2 IHC/FISH equivocal
b 1 HER2 IHC/FISH equivocal
c 5 HER2 IHC/FISH equivocal
Neoadjuvant Response in Molecular Subtypes 3263
Neoadjuvant Treatment
A total of 280 (66 %) patients received NCT without
trastuzumab of whom the majority (92 %) received a reg-
imen containing anthracyclines and taxanes; 123 (29 %)
patients received NCT with trastuzumab (2 patients
received trastuzumab and pertuzumab), 65 % received
docetaxel/carboplatin/trastuzumab (TCH), and 35 % dox-
orubicin/cyclophosphamide followed by docetaxel/
trastuzumab (AC-TH). Three (\1 %) patients received
NCT and NET, 20 (5 %) NET (Tables 3, 4).
Response Rates to Neoadjuvant Chemotherapy
Treatment
The overall pCR rate to NCT was 99 of 403 (25 %). The
pCR rates of the IHC/FISH subclasses and BluePrint/
MammaPrint molecular subclasses are shown in Fig. 1a.
Note that 23 patients were not treated with NCT, and these
patients are not included in the response to neoadjuvant
chemotherapy analyses. The pCR rate in BPLuminal
patients who received NCT was 11 of 189 (6 %: 2 %
BPLuminalA and 7 % BPLuminalB) versus 18 of 188
(10 %) in IHC/FISH HR?/HER2- patients. The pCR rate
in BPHER2 patients was 39/74 (53 %) and was signifi-
cantly superior to the 47/123 (38 %) in IHC/FISH HER2?
patients (p = 0.047). Of the 140 BPBasal patients,
including the 35 reclassified from the IHC/FISH HR?/
HER2- and 17 from the IHC/FISH HER2? categories, all
received NCT; 49 (35 %) had a pCR, similar to the pCR
rate 34/92 (37 %) seen in the patients originally designated
TN by IHC/FISH.
Response Rates for Reclassified Patients
The pCR rate in IHC/FISH HR?/HER2- (conventional
luminal) patients was 10 %. However, 35 of 188 (19 %) of


































































FIG. 1 a pCR rates and major subtype re-assignments for patients
classified by BluePrint/MammaPrint molecular subtyping compared
with IHC/FISH assessed subgroups. The analysis includes only
patients treated with NCT (n = 403). The two major subtype
reassignments were (A) conventional luminal (HR?/HER2-)
patients, 35 of 188 (19 %) patients reclassified by BluePrint as Basal
(arrow A) and (B) conventional HER2? patients, 36 of 123 (29 %)
reclassified by BluePrint as Luminal (arrow B). b pCR rates and
major subtype reassignments for conventional HER2?/HR? (‘‘triple
positive’’) patients (95 % treated with NCT/trastuzumab). Thirty-six
of 75 (48 %) of conventional HER2?/HR? patients were reclassified
by BluePrint as Luminal—with only 1 pCR (3 %) to NCT (arrow A).
Thirty-three of 75 (44 %) of conventional HER2?/HR? patients
were classified by BluePrint as HER2, with a pCR rate to NCT of
45 % (arrow B). Six conventional HER2?/HR? patients were
reassigned to BPBasal (not shown)
TABLE 3 Neoadjuvant treatment received by BluePrint/Mamma-
Print molecular subtyping
Treatment BluePrint/MammaPrint Total
Luminal A Luminal B HER2 Basal
NCT 37 116 4 123 280
NCT/trastuzumab 7a 29b 70 17c 123
NCT/NET 0 3 0 0 3
NET 15 5 0 0 20
Total 59 153 74 140 426
a 7 IHC/FISH HER2? patients
b 25 IHC/FISH HER2? patients, 2 IHC/FISH HER2 equivocal
patients, and 2 with a positive mRNA HER2 read out
c 16 IHC/FISH HER2? patients and 1 IHC/FISH HER2 equivocal
patient







NCT 183 6 91 280
NCT/
trastuzumab
5a 117 1b 123
NCT/NET 3 0 0 3
NET 20 0 0 20
Total 211 123 92 426
a 2 IHC/FISH equivocal patients, 1 BluePrint HER2, and 2 with a
positive mRNA HER2 read out
b 1 IHC/FISH equivocal patient
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as Basal (Fig. 1a, arrow A). The pCR rate in these patients
was 26 % (Table 5).
Of conventional HER2? patients, 36 of 123 (29 %)
were reclassified by BluePrint as Luminal (Fig. 1a, arrow
B). All 36 came from the subset of IHC/FISH HER2?
patients who were HR? (‘‘triple positive’’). When IHC/
FISH HER2? patients were subdivided into those who
were hormone receptor-positive (HER2?/HR?) versus
negative (HER2?/HR-), the pCR rate in HER2?/HR?
was inferior to that for HER2?/HR-: 20/75 (27 %) versus
27/48 (56 %; p = 0.001). Of the 75 HER2?/HR? (‘‘triple
positive’’) patients, the 36 who were reclassified by Blue-
Print as Luminal had only 1 pCR (3 %) to NCT (32
received NCT/trastuzumab) (Fig. 1b, arrow A). This pCR
rate is significantly lower than the pCR rate of 45 % in the
33 HER2?/HR? patients (44 %) who are BPHER2 and
received NCT/trastuzumab (p \ 0.000; Fig. 1b, arrow B).
The pCR rate in IHC/FISH HER2?/HR? reclassified as
BluePrint Luminal was 0 % in Luminal A and 4 % in
Luminal B (Table 5). Of six IHC/FISH HER2?/HR?
patients reclassified as BPBasal, four had a complete
response (all were treated with NCT and trastuzumab).
Response Rates to Endocrine Treatment
Twenty of 426 (5 %) patients received NET. All
patients were IHC/FISH HR?/HER2- and the PR rate was
65 %. Fifteen of 20 (75 %) patients were BluePrint
Luminal A and 12 (80 %) patients had a PR. Only one of
the five BluePrint Luminal B patients had a PR to NET.
Three IHC/FISH HR?/HER2- and BluePrint Luminal B
patients received NET and NCT and two had a PR.
DISCUSSION
Molecular subtype has been suggested as a superior
classification to determine treatment strategy for breast
cancer patients. Neoadjuvant chemosensitivity and endo-
crine sensitivity rates are increasingly accepted as
surrogates for efficacy, especially if substantial impact can
be demonstrated. In this present study when using Blue-
Print and Mammaprint for defining molecular subtypes,
22 % (94/426) of breast cancer patients are classified in a
different subgroup compared with conventional assess-
ment. Treatment was at the discretion of the physician
adhering to NCCN-approved or other established, peer-
reviewed regimens and is mostly in line with conventional
assessment. This reclassification of patients leads to an
improved distribution of response rates in the different
subgroups of patients: a lower pCR rate for BPLuminal
patients compared with IHC/FISH-defined conventional
luminal patients, with more responsive patients reassigned
to the HER2 and Basal categories.
BluePrint/MammaPrint subtypes have previously been
compared to quality-controlled, centrally assessed IHC/
FISH subtypes in the first 621 patients of the MINDACT
trial.4 This analysis showed that 58 % of IHC/FISH
HER2? patients were classified as BluePrint HER2 which
is almost identical to the 57 % in the present analysis. This
indicates that 42–43 % of conventional HER2? patients
are classified differently by BluePrint molecular subtyping.
Conventionally classified TN patients using central IHC/
FISH pathology were Basal by BluePrint in 98 % of cases,
which is similar to the 96 % in this study. BluePrint almost
always reconfirms the basal phenotype of TN patients. As
for conventional luminal patients (central pathology
determined HR?/HER2-) 96 % also were classified as
BluePrint Luminal, 14 % lower in the current study
(82 %). The latter higher discordance rate between con-
ventionally classified luminal and BluePrint Luminal
patients might be related to the variability in IHC ER and/
or PR assessment at local institutions. Accurate test per-
formance is crucial, yet there is evidence of wide
variability in test performance and inaccurate results (fal-
sely negative or falsely positive) of up to 20 %.5
The observed difference in clinically assessed subgroups
of early stage breast cancer patients compared with
molecular sub classification of patients has been reported
TABLE 5 BluePrint/MammaPrint subtype pCR rates within the different conventionally classified subtypes (IHC/FISH) treated with NCT
(n = 403)
IHC/FISH HR?/HER2- HER2?/HR? HER2?/HR- TN Total
n pCR (%) n pCR (%) n pCR (%) n pCR (%) n pCR (%)
Total 188 10 75 27 48 56 92 37 403 25
Molecular subtypes
Luminal A 36 3 8 0 – – – – 44 2
Luminal B 115 7 28 4 – – 2 50 145 7
HER2 2 0 33 45 37 65 2 0 74 53
Basal 35 26 6 67 11 27 88 38 140 35
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also by others, for instance for subtyping with the intrinsic
molecular signature6 and the PAM50 signature.7,8 And
even though some of the discordance could potentially be
ascribed to technical issues such as test performance and
the fact that assessments from different tumour areas are
being compared, the discordance also seems to indicate a
‘true’ difference in assigning patients by these 2 types of
assessments. Molecular classification is designed such that
it captures the true biologic profile regulated by ER/PR/
HER and it measures these pathways by measuring a larger
number of related genes. The BluePrint 80-gene classifier
identifies ‘‘functional’’ molecular subtype based on intact
molecular pathways associated with concordant mRNA
and protein expression (1).
Clinical Impact
The two largest groups of reassigned patients with
potential clinical implications are those conventional
HER2? patients, who are not classified as HER2 by Blue-
Print, and the conventional luminal (HR?/HER2-) patients
who are reclassified by BluePrint to Basal. The BluePrint
HER2 group of patients show a significantly higher pCR rate
than that for patients classified as HER2? by IHC/FISH,
with less responsive patients reassigned to the BluePrint
Luminal category. All of these reassigned patients come
from the HR? subset of conventional HER2? patients.
Several studies have suggested that pathologic complete
response was not particularly prognostic for ER?, HER2?
breast cancers, suggesting the possibility that a subset of
HER2?, ER? breast cancers are driven primarily by ER,
and biologically behave more like HER2-, ER? breast
cancers. Identification of this subset of HER2? breast
cancers is essential to avoid overtreatment of patients with
small HER2?, ER? breast cancers, who may be optimally
treated with endocrine therapy alone, or in combination
with a HER2-directed agent, thereby avoiding the use of
chemotherapy.9 In our study, 75 patients are IHC/FISH
HER2?/HR? of whom 36 (48 %) are BluePrint Luminal
with a significantly lower pCR rate (3 %) to NCT/trast-
uzumab versus the 33 IHC/FISH HER2?/HR? patients
(44 %) who are BluePrint HER2 (pCR = 45 %). Therefore
with BluePrint functional subtype IHC/FISH HER2?/
HR? patients are subdivided into BPLuminal with a poor
response to NCT/trastuzumab and BPHER2 with a good
response to NCT/trastuzumab.
An additional 17 (14 %) of 123 conventional HER2
patients were reclassified BPBasal. This finding is likely to
become more important as biological subsets within the
TN/Basal subtype are delineated.
Many of the conventional luminal patients were
reclassified as Basal by BluePrint, enlarging the Basal
category while the pCR rate was maintained. This group of
conventional luminal patients are reported to have low
expression levels of ER and PR and also has been identified
by other methods of molecular classification 4,10. For this
group of patients conventionally identified as endocrine
responsive who are reclassified to the Basal subgroup, it
makes sense to consider neoadjuvant chemotherapy.
We have adhered to the recently more stringent definition
of pCR: ypT0/is ypN0 as suggested by Cortazar et al. 11. As
suggested in this large pooled data analysis, our results can
be used to compare response rates as a measure of outcome
on a patient level. The overall pCR rate in our study (25 %)
is comparable to the overall pCR rate in the Cortazar pooled
analyses (22 %). IHC/FISH HR?/HER2- had a pCR rate
of 8 % (grade 1 and 2) and 16 % (grade 3) in the pooled
analyses, which is similar to the IHC/FISH HR?/HER2-
pCR rate of 10 % in our study. Response rates for IHC/FISH
HER2?/HR? (31 vs. 27 %), HER?/HR- (50 vs. 56 %),
and TN (34 vs. 37 %) also were comparable. In the pooled
analyses of Cortazar et al. 11. The correlation between pCR
rate and long-term outcome was strongest for HER2?/HR-
patients and TN patients. A limitation of our study is that
long-term outcome data are not yet available.
In a retrospective pooled analysis of MammaPrint and
BluePrint in patients enrolled in four neoadjuvant chemo-
therapy trials pCR rate correlated with DMFS in BluePrint
HER2 and Basal patients and not in BluePrint Luminal
patients.3 The current study confirms the unique identifi-
cation of a group of patients classified as Luminal A using
Molecular Subtyping with MammaPrint and BluePrint who
have an extremely low pCR rate (2 %) and who have
previously been shown to have excellent survival.
These findings confirm the more accurate identification
of molecular subgroups for treatment decision by the
80-gene BluePrint functional subtype classifier, which
therefore may serve as a better guide for neoadjuvant
treatment than standard, local IHC/FISH assay. Approxi-
mately one in five conventional ‘‘luminal’’ patients are
reclassified as BPBasal and approximately half of con-
ventional HER2? HR? patients are reclassified as
BPLuminal.
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